Mechanistically, acetyltransferase p300 inhibition is associated with decreased transcriptional activity of MEF2A and reduced expression of ANP and β-MHC compared to controls further indicating the potentiality of acetyltransferase inhibitor as an epidrug for the therapy of pressure overload-induced cardiac hypertrophy and heart failure [54]. This evidence concerns the gene MEF2A and cardiac hypertrophy.